Full-length cDNA for plasminogen activator inhibitor (PAI-1) was isolated from a human umbilical vein endothelial cell (HU-VEC) lambda gtl1 cDNA library. Three overlapping clones were identified by immunologic screening of 10' recombinant phage using a rabbit anti-human fibrosarcoma PAI-1 antiserum. The fusion proteins encoded by these three clones also react strongly with a monoclonal mouse anti-human fibrosarcoma PAI-1 antibody. By nucleotide sequence analysis, PAI-1 cDNA encodes a protein containing 402 amino acids with a predicted, nonglycosylated molecular mass of 45 kD. Identity of this material as authentic PAI-1 was confirmed by the presence of high level homology with the primary amino acid sequence of an internal peptide prepared from purified rat hepatoma PAI-1. The predicted amino acid sequence also reveals extensive homology with other members of the serine protease inhibitor gene family. Cultured HUVECs contain two PAI-I mRNA species, both encoded by a single gene, differing by 1 kb in the 3' untranslated region. The PAI-i gene is located on human chromosome 7.
Introduction
Fibrinolysis is regulated, in part, by a balance between plasminogen activators (tissue plasminogen activator [tPA]' and urokinase PA [uPA] ) and specific, rapidly acting inhibitors, plasminogen activator-inhibitors (PAIs) (1) . Two major types of fast-acting PAI have been distinguished on the basis ofbiochemical and immunological properties, and designated PAI-1 and PAI-2.2 PAI-1 is a 50-54-kD, acid-stable glycoprotein found in plasma, platelets, endothelial cells, hepatoma cells, and fibrosarcoma cells (2) (3) (4) (5) (6) (7) (8) (9) . Vascular endothelial cells may represent the major site of synthesis for plasma PAI-I (1, 3, 5) . In human umbilical vein endothelial cells (HUVECs), PAI-I activity is induced by thrombin, endotoxin, and interleukin-1 (10-12) and gonucleotide primers for construction of sequencing deletions (23) were purchased from International Biotechnologies, Inc. Radioisotopes and DNA sequencing reagents were purchased from Amersham Corp. (Arlington Heights, IL). Bluescribe transcription vector and T7 and T3 RNA polymerases were purchased from Stratagene (San Diego, CA). Guanylyltransferase was purchased from Bethesda Research Laboratories (Gaithersburg, MD). The in vitro translation kit was purchased from Promega Biotec (Madison, WI). Staphylococcus aureus protein A was obtained from Zymed Laboratories, Inc. (San Francisco, CA). All other reagents were of the best grade commercially available.
Immunoscreening ofcDNA library. The construction ofthe HUVEC lambda gtl 1 cDNA library used in these studies has been previously reported (24, 25) . Immunoscreening ofrecombinant phage was performed by the method of Young and Davis (26) except that preincubation and antibody treatment of filters was performed in BLOTTO (10 mM Tris, 140 mM NaCI, and 5% Carnation nonfat powdered milk [pH 7 .5]) (27) .
To remove any background anti-Escherchia coli antibody activity, anti-PAI-I antibody was diluted in BLOTTO and absorbed against nitrocellulose filters that had been presoaked with a lysate prepared from E. coli infected with wild type lambda gtl 1 (26) . Isopropyl thio-beta-D-galactopyranoside-induced phage plaques were transferred to nitrocellulose filters (24, 26) and incubated for 3 h at room temperature in BLOTTOcontaining anti-PAI-l antibody (at a final dilution of 1:100 for polyclonal antibody [Ab] 7 .4] containing 20% methanol vol/vol, 0.06% 4-chloro-l-naphthol wt/vol, and 0.03% H202 vol/vol) (28) . Positive clones were plaque purified through one to two additional rescreening steps, subcloned into pUC 13
and analyzed by restriction enzyme digestion using standard methods (29) .
Northern and Southern blot analysis. cDNA fragments were radiolabeled with [32P]dCTP by random priming (30) . Preparation of RNA and DNA, and Northern and Southern blot analyses were performed, as previously described (24, 29) . DNA sequence analysis. Full-length cDNA clones PAIB4 and PAIB6 were sequenced in Ml 3mp18 or MI3mpl9 by constructing nested deletions using the method of Dale et al. (23) . Sequence analysis for these and other clones (also subcloned into Ml3mplO, M13mpl8, or MI3mpl9) was performed by the method of Sanger (31, 32) . Sequence analysis was performed with the IBI-Pustell software package (International Biotechnologies, Inc.) (33) , except for homology calculations, which used DNASTAR (Madison, WI) software using the Needleman-Wunsch algorithm (34) .
Fusion protein and in vitro translation studies. Beta galactosidase-PAI-I fusion protein from antibody positive clones was prepared as previously described (24, 26) and analyzed by SDS-polyacrylamide gel electrophoresis (PAGE) and Western blotting using standard methods (35) . RNA was transcribed in vitro from full-length cDNA clones PAIB4 and PAIB6 (subcloned into the transcription vector Bluescribe) using T7 and T3 RNA polymerase, and the RNA capped with guanylyltransferase using the conditions recommended by the manufacturers. This material was used in an in vitro translation assay, radiolabeled by incorporation of [35S]methionine. Translated protein was immunoprecipitated using the purified IgG fraction of rabbit polyclonal anti-human fibrosarcoma PAI-l. 4.7 Mg of IgG was added to 70 ,l of translation mix and allowed to incubate for 30 min at room temperature and 2 h at 40C. IgG was recovered using insoluble S. aureus protein A, the bound proteins released into SDS-PAGE sample buffer by heating (1000C for 2 min), and then examined by SDS-PAGE and autoradiography.
Purification and amino acid sequence analysis ofrat PAI-1. HTC rat hepatoma cell PAI-I was purified by immunoaffinity chromatography from serum-free medium conditioned by cells incubated in the presence of 10-' M dexamethasone (Rafferty, U., R. Zeheb, P. Andreasen, and T. Gelehrter, manuscript in preparation). The functional integrity ofthe purified PAI-l was confirmed using a coupled esterolytic assay (9, 1 1), and reverse fibrin autography (2) . Peptide fragments were generated by treatment with cyanogen bromide, according to the method of Koide and Ikenake (36) . One such fragment was purified by reverse-phase high pressure liquid chromatography and subjected to primary amino acid sequence determination (performed at the University of Michigan Protein Sequencing Facility [37] ).
Chromosomal localization. Chromosome suspensions were prepared from a lymphocyte cell line in Tris-spermine buffer and stained with the 4'-6-bis(2'-imidazdinyl-4H,5H)-2-phenylindole-chromomycin A3 stain pair (38) . 30,000 chromosomes of each type were sorted directly onto a single spot of a nitrocellulose filter paper using a Becton-Dickinson (Mountainview, CA) FACS IV sorter with a triple laser optical bench (39) . The filter-bound chromosomal DNA was denatured, neutralized, prehybridized, and hybridized in 10% dextran sulfate (38) for 18 h to random-primer-labeled PAIB6 insert (30) . After washing to remove excess probe, the gene-specific signal was detected by autoradiography (38) .
Results
Expression cloning of PAI-I cDNA. One million recombinant clones from a lambda gtl 1 cDNA library constructed from HU-VEC mRNA were screened using a polyclonal rabbit anti-human PAI-I antisertim. Six positive clones were initially identified. Three of these clones (PAI9, PAI 17, and PAI20) were also positive when screened with a mouse anti-human monoclonal PAI-1 antibody, and these same three clones also contained overlapping cDNA sequence as determined by cross hybridization with radiolabeled insert. Clone PAIl9 encoded a fusion protein that also reacted with anti-fibronectin antibody and was probably due to background anti-fibronectin activity in our anti-PAI-l antibody. Clones PAI7 and PA1l8 cross-hybridized with each other but on Northern blot analysis of HUVEC mRNA recognized a single 1-kb mRNA species (data not shown), too small to encode human PAI-1, and thus were not examined further. Lysogens ofphage clones PAI9, PAI17, and PAI20 were prepared in E. coli host Y-1089, and fusion protein synthesis induced with isopropyl thio-beta-D-galactopyranoside. Fig. 1 shows SDS-PAGE analysis of bacterial lysate prepared from one of these cultures. The wild type beta-galactosidase is replaced by a larger fusion protein. Western blot analyses using both the polyclonal and monoclonal anti-PAI-1 antibodies show immunoreactivity only with the fusion protein (Fig. 1) .
The insert from clone PAI17 was radiolabeled and used as a probe to rescreen the cDNA library. Positive clones were identified with an abundance of -1:1000. 20 new phage clones were isolated, most containing large inserts falling into two size classes of -3 and 2 kb, respectively. Characterization ofPAI-I cDNA. Radiolabeled insert from clone PAI 17 was used in Northern blot analysis of mRNA from HUVECs, and the results are shown in Fig. 3 A (lane 1). Two mRNA species, -3 and 2 kb, are detected, with roughly equal intensity. Southern blot analysis ( Fig. 3 B ) also using PAI17 insert, detects a single band consistent with a single gene product. RNA produced in vitro from clones PAIB4 and PAIB6, representative of the 3-and 2-kb mRNA species respectively, were used as template in an in vitro translation system. Fig. 4 shows the results of this experiment with PAIB4 as template. Identical results were obtained with PAIB6 (not shown). Both RNA species direct the synthesis of a 40-45-kD protein, which is immunoprecipitated by anti-PAI-l antibody.
Nucleotide sequence analysis. The complete sequence of clone PAIB4 was determined (confirmed by analysis of both strands), as well as partial sequence for PAI 17, PAI9, PAI20, PAIB6, and several additional clones. Amino acid residues 376-390 show identity at 10 positions to a small region of primary peptide sequence obtained from purified rat PAI-1, including a segment of perfect homology for 8/8 residues (Fig. 5 A) . Comparison ofthe predicted amino acid sequence with that of other reported serine protease inhibitors shows a high degree of homology between PAI-1 and other members of the serine protease inhibitor gene family (Table I) .
Chromosomal localization. The PAI-l gene was mapped by hybridization analysis of mitotic human chromosome suspensions sorted directly onto nitrocellulose filters. In two complete filter panels sorted from two different cell lines, GM 130 and GM 131, gene-specific hybridization was seen only to the spot containing chromosome 7 DNA. 
Discussion
The vascular endothelial cell may represent the major site of synthesis for plasma PAI (1, 3, 5) . PAI-l has been shown to constitute as much as 2.5-12% oftotal protein synthesis in bovine. aortic endothelial cells (5) , and may serve as a major control point in the regulation of fibrinolysis via its rapid interaction with tPA (1, 6, 9) . Overproduction of PAI-l may contribute to the pathogenesis of human thromboembolic disease (17) (18) (19) [34] ) is no higher than between either of these species and the other members of the SERPIN family (see Table I hydrophobic portion ofthe molecule that immediately precedes the hydrophilic domain recognized by the monoclonal Ab IA5E2 (Fig. 5 B) . This may represent a region of unique function shared by these two related proteins.
The three primary antibody positive clones, PAI17, PAI20, and PAI9, all overlap at the DNA level (Fig. 2) (Fig. 5 B) , and may represent upstream. However, the 68-nucleotide-long 5' untranslated reDs (Fig. 3 A) is '-3 kb long.
gion found in this sequence is an average length for eukaryotic s contains 2,869 nucleotides mRNA, and the sequence immediately preceding the proposed " complete PAI-1 sequence.
initiator codon is consistent with the consensus sequence prorminus of most eukaryotic posed by Kozak (45) . A second ATG present only two codons ice as well as the highly condownstream would be expected to function poorly as an initiator UAAA, which precedes the codon, with a pyrimidine present at position -3 (45) . The canilso not present at the 3' end didate initiator codon is followed by a typical hydrophobic leader This probably represents an sequence containing a core of 13 hydrophobic residues (codon hesis. Multiple phage clones 6-18) with a predicted cleavage site after the alanine at codon ry, both for PAI-l as well as 23 (46) . This sequence encodes a preprotein of402 amino acids, cell mRNAs. Most (Zeheb, R., and T. Gelehrter, unpublished data). PAI-l is known e of a small amount of adto be glycosylated (3, 8) and the sequence predicts three potential first ATG codon appears at N-glycosylation sites (with the canonical sequence Asn-X-Ser/ cause this putative initiator Thr where X is not Pro) (40) . Interestingly, the presence of a Val in rat PAI-1, in place of Pro389 in the human (the single difference in a 10 amino acid segment), creates an additional potential N-glycosylation acceptor site in the rat protein (Fig. 5 A) . (41, 44) . In contrast, the distribution of introns in the serine protease inhibitor gene family is difficult to fit into a simple model. The number of introns varies widely, and the precise location of these introns is not highly conserved (43, 50) . The number and placement of introns for the two forms of PAI, PAI-1 and PAI-2, may shed further light on the process of SER-PIN intron evolution. The availability of cDNA and genomic PAI-I sequences should also prove useful for the evaluation of possible genetic defects in PAI-I as major risk factors for thromboembolic diseases in humans.
